CD160 Expression in Corneal Vessels

Launched by CHU DE REIMS · Aug 11, 2021

Keywords

ClinConnect Summary

This clinical trial is studying the role of a specific protein called CD160 in the blood and lymphatic vessels of the cornea, particularly how it might be linked to corneal graft rejection. Corneal graft rejection can occur after a corneal transplant, and understanding the factors involved could help improve outcomes for patients. Researchers believe that CD160 might play a role in this process and are looking to see how it's expressed in patients’ corneal vessels.

To be eligible for this trial, participants need to be at least 18 years old and scheduled to undergo a particular type of eye surgery at a hospital in Reims, France. There are no specific exclusions, so most patients who meet the age and surgery criteria can participate. If you join the trial, you can expect to provide informed consent and participate in assessments related to your condition. This research aims to enhance our understanding of corneal graft rejection, which could lead to better treatments in the future.

Gender

ALL

Eligibility criteria

• inclusion criteria :
• • 18-year-old or more patients
• • enrolled for penetrating keratoplasty or deep anterior lamellar keratoplasty surgeries at the Robert Debré University Hospital, Reims, France
• * considered able to give an informed written consent exclusion criteria :
• • none